Squarepoint Ops LLC Has $126,000 Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Squarepoint Ops LLC decreased its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 83.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,134 shares of the biopharmaceutical company’s stock after selling 118,802 shares during the quarter. Squarepoint Ops LLC’s holdings in Sage Therapeutics were worth $126,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Picton Mahoney Asset Management grew its stake in shares of Sage Therapeutics by 126.0% in the 4th quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 3,581 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Sage Therapeutics in the 4th quarter worth $49,000. Ieq Capital LLC bought a new stake in shares of Sage Therapeutics in the 4th quarter worth $57,000. US Bancorp DE grew its stake in shares of Sage Therapeutics by 22.3% in the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 2,268 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its holdings in shares of Sage Therapeutics by 21.6% in the 4th quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company’s stock worth $75,000 after buying an additional 2,446 shares during the last quarter. Institutional investors own 99.22% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on SAGE. HC Wainwright reaffirmed a “neutral” rating and set a $12.00 price objective (down from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Wall Street Zen downgraded shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Canaccord Genuity Group decreased their price objective on shares of Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating on the stock in a research report on Wednesday, February 12th. Scotiabank reduced their price target on shares of Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a research report on Wednesday, February 12th. Finally, Wedbush restated a “neutral” rating and issued a $6.00 target price on shares of Sage Therapeutics in a report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $8.87.

Sage Therapeutics Price Performance

Shares of NASDAQ SAGE opened at $6.81 on Tuesday. The stock’s 50-day moving average is $6.97 and its two-hundred day moving average is $6.84. Sage Therapeutics, Inc. has a 1-year low of $4.62 and a 1-year high of $13.47. The company has a market cap of $426.45 million, a price-to-earnings ratio of -1.03 and a beta of 0.18.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.02). The business had revenue of $14.06 million for the quarter, compared to analyst estimates of $14.12 million. Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The company’s revenue was up 78.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.80) earnings per share. Equities research analysts anticipate that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current fiscal year.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.